Quan Funds is a family of absolute-return funds based in Geneva, Switzerland. Its flagship Quan Technology Fund is a crossover fund investing in private and public technology companies, including semiconductors, optical, and deep tech.
69% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $122.9M (across 31 rounds with reported amounts).
Portfolio
22
Fund Size
—
Top Stage
Series B
Last 12 Mo
5
Team
ES
Ed Schneider
Director
RK
Rob Kalman
Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
36 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 NextCure | Series B | $500M | Aug 2026 |
 Alebund | Series C | — | Jun 2026 |
 Windward Bio | Unknown | $165M | May 2026 |
 Windward | Unknown | $165M | May 2026 |
 Pinnacle Medicines | Series B | $89M | Mar 2026 |
 Avenzotx | Series B | $60M | Sep 2025 |
 Lumotive | Series B | $45M | Feb 2025 |
| Windward Bio | Series A | $200M | Jan 2025 |
| Lumotive | Series B | — | Jan 2025 |
 Avenzo Therapeutics | Series B | $60M | Jan 2025 |
| Windward | Series A | $200M | Jan 2025 |
| Avenzo Therapeutics | Unknown | $386M | Nov 2024 |
| Avenzotx | Unknown | $386M | Nov 2024 |
 Zenas BioPharma | Series C | $200M | May 2024 |
| Zenas BioPharma | Series C | $200M | Jan 2024 |
 Adcentrx Therapeutics | Series A | $51M | Dec 2023 |
 Crescendo Biologics | Series A | $32M | Jan 2023 |
 Oricell Therapeutics | Series B | $120M | Aug 2022 |
 Interius BioTherapeutics | Series A | $76M | May 2021 |
 Kira Pharmaceuticals | Series B | $53.5M | Jan 2021 |
 Design Therapeutics | Series B | $125M | Jan 2021 |
| Alebund | Series B | $60M | Jan 2021 |
| Interius BioTherapeutics | Series A | $76M | Jan 2021 |
| Design Therapeutics | Series A | $45M | Jan 2020 |
 Eluminex | Series A | $50M | Jan 2020 |
Page 1 of 2
Top Co-Investors
SR One13 shared
OrbiMed13 shared
RA Capital Management11 shared
Sofinnova Partners8 shared
LAV7 shared
New Enterprise Associates7 shared
Vivo Capital6 shared
Foresite Capital6 shared
Delos Capital6 shared
Surveyor Capital6 shared
Omega Funds5 shared
Pivotal Life Sciences5 shared
ArrowMark Partners5 shared
Longwood Fund5 shared
Swisscom Ventures4 shared
Sanofi Ventures4 shared
Novo Capital4 shared
Sands Capital4 shared
Deep Track Capital4 shared
Last updated: 20 October 2026